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Abstract
Inflammation of the central nervous system (CNS) induces endothelial blood–brain barrier
(BBB) opening as well as the formation of a tight junction barrier between reactive astro-
cytes at the Glia Limitans. We hypothesized that the CNS parenchyma may acquire protec-
tion from the reactive astrocytic Glia Limitans not only during neuroinflammation but also
when BBB integrity is compromised in the resting state. Previous studies found that astro-
cyte-derived Sonic hedgehog (SHH) stabilizes the BBB during CNS inflammatory disease,
while endothelial-derived desert hedgehog (DHH) is expressed at the BBB under resting
conditions. Here, we investigated the effects of endothelial Dhh on the integrity of the BBB
and Glia Limitans. We first characterized DHH expression within endothelial cells at the
BBB, then demonstrated that DHH is down-regulated during experimental autoimmune
encephalomyelitis (EAE). Using a mouse model in which endothelial Dhh is inducibly
deleted, we found that endothelial Dhh both opens the BBB via the modulation of forkhead
box O1 (FoxO1) transcriptional activity and induces a tight junctional barrier at the Glia Limit-
ans. We confirmed the relevance of this glial barrier system in human multiple sclerosis
active lesions. These results provide evidence for the novel concept of “chronic neuroinflam-
matory tolerance” in which BBB opening in the resting state is sufficient to stimulate a pro-
tective barrier at the Glia Limitans that limits the severity of subsequent neuroinflammatory
disease. In summary, genetic disruption of the BBB generates endothelial signals that drive
the formation under resting conditions of a secondary barrier at the Glia Limitans with pro-
tective effects against subsequent CNS inflammation. The concept of a reciprocally regu-
lated CNS double barrier system has implications for treatment strategies in both the acute
and chronic phases of multiple sclerosis pathophysiology.
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Introduction
In a healthy individual, the central nervous system (CNS) parenchyma is protected from the
peripheral circulation by the blood–brain barrier (BBB), which tightly regulates the entry and
exit of soluble factors and immune cells [1]. Importantly, during multiple sclerosis, the abnor-
mal permeability of the BBB allows penetration into the CNS parenchyma of inflammatory
cells and soluble factors such as autoantibodies, cytokines, and toxic plasma proteins, which
drive lesion formation and acute disease exacerbation [2,3]. Therefore, identifying key mecha-
nisms that promote BBB tightness is currently considered to be a main strategy for controlling
leukocyte and humoral entry, preventing acute relapse and disability progression in multiple
sclerosis.
Previous studies have identified the Hedgehog (HH) pathway as a regulator of BBB integrity
in multiple sclerosis, HIV, and stroke [4–7]. Desert hedgehog (DHH) is expressed constitu-
tively at the BBB in adults [8] and belongs, together with Sonic hedgehog (SHH) and Indian
hedgehog (IHH), to the HH family of morphogens, identified nearly 4 decades ago in Dro-
sophila as crucial regulators of cell fate determination during embryogenesis [9]. The interac-
tion of HH proteins with their specific receptor Patched-1 (PTCH1) derepresses the
transmembrane protein Smoothened (SMO), which activates downstream pathways including
the canonical HH pathway leading to the activation of Gli family zinc finger (Gli) transcription
factors, and the so-called noncanonical HH pathways, which are independent of SMO and/or
Gli [10].
Interestingly, a wealth of literature published during the last decades has enabled a change
in the vision of BBB structure and integrity, which has expanded to include contributions
from both barrier properties of the vascular endothelial cells and the astrocytic end feet of the
neurovascular unit. Within the neurovascular unit, substantial intercellular communication
network involves the vascular endothelial cells and astrocytic end feet, as well as the pericytes
and basement membranes within the perivascular space (PVS) [11–13]. How these signals reg-
ulate the passage of soluble factors and cells into and out of the CNS is not completely under-
stood and is of considerable translational interest to the field of neuroimmunology. Regulatory
mechanisms at the BBB include solute transporters and receptor-mediated transcytosis, and
immune cells are actively prevented from crossing the BBB by low levels of immune receptors
that normally permit immune trafficking. Once soluble factors and immune cells penetrate the
BBB, they circulate within the PVS, a region between the basal basement membrane of the
endothelial cell wall and the parenchymal basement membrane abutting the astrocyte end feet
[14,15]. While it is now well established that BBB breakdown leads to soluble factor and
inflammatory cell infiltration into the PVS during neuropathology, the role of the Glia Limit-
ans is more complex. Indeed, astrocytes, described as reactive, may demonstrate opposing
roles in both recruiting and restricting neuroinflammatory infiltration depending on the con-
text [16]. Specific reactive astrocyte behaviors are likely determined by signaling events that
vary with the nature and severity of CNS injury or disease. Specifically, in multiple sclerosis as
well as Alzheimer’s and Parkinson diseases, it has been shown that reactive astrocytes, on one
hand, produce pro-inflammatory and pro-permeability factors and on the other hand, neuro-
protective factors [17–19].
Astrocyte barrier properties are not as well characterized as those of the BBB. However, sev-
eral groups have highlighted barrier properties at the Glia Limitans [20–22]. Notably, endfoot–
endfoot clefts, similar to those observed between endothelial cells at the BBB, have been
described at the Glia Limitans and shown to be responsible for the sieving effect observed
between the distribution of small and large Dextrans [23]. Moreover, under neuroinflamma-
tory conditions, immune cell trafficking across the Glia Limitans is necessary for clinical
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experimental autoimmune encephalomyelitis (EAE) [21]; indeed, matrix metalloproteinase
(MMP)-2 and MMP-9 proteolytically cleave dystroglycan, which anchors astrocyte end feet to
the Glia Limitans basement membrane via binding to extracellular matrix molecules, allowing
infiltrating leukocytes to penetrate the parenchyma [24]. Additionally, it has been shown that
the scavenger receptor CXCR7 is up-regulated on the inflamed BBB endothelium, facilitating
mobilization of T cells from the PVS into the CNS parenchyma [25]. Altogether, these data
demonstrate that both the endothelial BBB and its basement membrane, along with the Glia
Limitans and the parenchymal basement membrane, are required for immune cell trafficking
across the neurovascular unit. Strikingly, our recent work has given considerable attention to a
new property of reactive astrocytes: the expression of tight junction proteins (notably Claudin4
(CLDN4)) under inflammatory conditions [26]. This result provides yet another argument in
favor of astrocytic barrier properties.
The first objective of our study was to decipher the role of the morphogen DHH in main-
taining BBB tightness. The second objective was to demonstrate that a double barrier system
comprising both the BBB and Glia Limitans is implemented in the CNS and regulated by a
crosstalk going from endothelial cell to astrocytes using endothelial Dhh knockdown as a
model of permeable BBB.
Here, we first demonstrate that endothelial DHH expression is down-regulated during neu-
roinflammation and is necessary to maintain BBB tightness. We then show that BBB opening,
induced by Dhh knockdown, drives astrocyte CLDN4 expression, conferring barrier proper-
ties to the Glia Limitans, which results in the PVS entrapment of plasma proteins and inflam-
matory cells, both under physiological conditions and during pathology. Together, these data
identify the neurovascular unit as a double barrier system whose function is controlled by the
crosstalk between endothelial cells and astrocytes.
In conclusion, this work strengthens the concept of CNS double barrier system, unveiling
how signals at the endothelium drive astrocyte barrier properties to protect the parenchyma
during neuropathology. Consequently, taking into account both components of the neurovas-
cular unit is of translational interest and could open the way for new therapeutic strategies
notably to limit progressive multiple sclerosis pathology.
Results
DHH, but not SHH or IHH, is expressed by CNS microvascular endothelial
cells and down-regulated during chronic neuroinflammation
First, we showed that DHH is expressed at the BBB in vitro using mouse CNS MECs� (Fig 1A).
CNS MEC purity was assessed using platelet/endothelial cell adhesion molecule 1 (PECAM1)
and zonula occludens 1 (ZO1) as positive endothelial markers and smooth muscle actin
(SMA), neural/glia antigen 2 (NG2), cluster of differentiation 45 (CD45), ionized calcium
binding adaptor molecule 1 (IBA1), and glial fibrillary acidic protein (GFAP) as markers of
contamination by smooth muscle cells, pericytes, leukocytes, microglia, and astrocytes, respec-
tively (Fig 1A and S1A Fig). DHH expression at the BBB was verified in vivo using human cor-
tical sections from healthy donors (Fig 1B) and brain sections from C57BL/6 mice (S1B Fig).
SHH and IHH are not expressed in the healthy BBB, and DHH is known to be stored intracel-
lularly as well as being secreted [7]. Therefore, we here infer the CNS endothelial cells as the
source of DHH within the neurovascular unit. Next, we demonstrated that Dhh is severely
down-regulated at the BBB under inflammatory conditions both in vitro using human brain
microvascular endothelial cells (HBMECs) treated with interleukin-1β (IL-1β) (one of the
main pro-inflammatory cytokine implicated in multiple sclerosis pathophysiology) (Fig 1C
and S1 Data) and in vivo (Fig 1F and S1 Data) using a preclinical model of multiple sclerosis
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Fig 1. DHH is expressed by CNS MECs and down-regulated during chronic neuroinflammation. (A) Primary BMECs were
isolated from 12-week-old C57Bl/6 mice, and Dhh, Ihh, Shh, Pecam1, Sma, Ng2, Cd45, and Gfap expressions were quantified by
qRT-PCR (cycle threshold mean values). β-actin is used as a reference. (B) Human cortical sections from healthy donors were
obtain from the NeuroCEB biobank and immunostained with anti-CDH5 (in red), anti-PECAM1 (in red), and anti-DHH (in
green) antibodies. Nuclei were stained with DAPI (in blue). (C–E) HBMECs were cultured until confluency and starved for 24 h.
HBMECs were then treated with PBS (control condition) or IL-1β 10 ng/mL for 24 h and (C) DHH, (D) ICAM1, and (E)
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(MOG35-55) to induce chronic neuroinflammation in C57BL/6 mice. For this experiment, iso-
lated spinal cord microvessels underwent a digestion step followed by a CD45+ T cell depletion
step to discard inflammatory cell contamination induced by EAE (S1C and S1D Fig). Dhh
down-regulation at the BBB is associated with the up-regulation of endothelial activation
markers intercellular adhesion molecule 1 (Icam1) (Fig 1D–1G and S1 Data) and vascular cell
adhesion molecule 1 (Vcam1) (Fig 1E–1H and S1 Data) and with down-regulation of mRNA
markers of tight junctions (claudin5 (Cldn5) and Zo1) (Fig 1I, 1J and S1 Data).
Together, these data identify DHH as the only HH expressed in adults at the endothelial
BBB. Moreover, they highlight the fact that DHH expression is down-regulated at the BBB
during neuroinflammatory pathology.
Endothelial-specific Dhh inactivation induces down-regulation of adherens
junction CDH5 and tight junction CLDN5 ex vivo
To test the importance of endothelial DHH expression at the BBB, we conditionally disrupted
DHH expression in endothelial cells and examined the consequences on BBB integrity. To do
so, we used CNS MEC cultures isolated from Cdh5-CreERT2, DhhFlox/Flox mice (DhhECKO
mice), and DhhFlox/Flox control littermates, 2 weeks after inducing knockdown by intraperito-
neal injection of tamoxifen. There is no difference between DhhECKO and control mouse cell
culture viability (S1E, S1F Fig and S2 Data).
We first verified the efficiency of the knockout by measuring Dhh expression in primary CNS
MEC cultures obtained from DhhECKO and littermate controls and showed that Dhh expression is
strongly down-regulated in the knockout mice (Fig 2A and S1 Data). Moreover, CDH5, CLDN5,
and ZO1 junctions are disorganized in DhhECKO endothelial cells: In controls, CDH5, CLDN5,
and ZO1 display a well-defined pattern of sharp contours at endothelial cell–cell contacts. In con-
trast, in DhhECKO cultures, a broader, more irregular pattern is detected at endothelial cell–cell
contacts (Fig 2D–2F). This result is consistent with the previously documented phenotype using
small interfering RNA (siRNA) for DHH [8]. CDH5 and CLDN5 but not ZO1 are down-regu-
lated in DhhECKO CNS MECs compared to controls (Fig 2B, 2C and 2G–2I and S1 Data).
We concluded that endothelial DHH expression is necessary to maintain endothelial adhe-
rens and tight junction mRNA and protein expression level at the BBB and to maintain a well-
defined CDH5, ZO1, and CLDN5 pattern of sharp contours at endothelial cell–cell contacts.
DHH induces CLDN5 up regulation through the inhibition of FOXO1
transcriptional activity in vitro
We previously identified DHH as a factor facilitating the interaction between CDH5 and cate-
nin β1 (CTNNβ1) in endothelial cells [8], and others have shown that CDH5 interacts with
VCAM1 expression were quantified by qRT-PCR. (F–H) Twelve-week-old C57Bl/6 females (6 animals per group) were induced
with MOG35-55 EAE versus placebo. At day 13 post induction, mice were humanely killed, and spinal cord microvascular
endothelial cells were isolated. (F) Dhh, (G) Icam1, (H) Vcam1, (I) Cldn5, and (J) Zo1 expression were measured via qRT-PCR
in both groups (MOG35-55 versus placebo).
��P� 0.01, ����P� 0.0001 Mann–Whitney U test. The underlying data for Fig 1 can
be found in S1 Data (https://doi.org/10.6084/m9.figshare.12625034.v6). �It is important to note that CNS endothelial cells are
from a pooled source including both brain and spinal cord tissues. Therefore, the resulting cell cultures/lysates may be
heterogeneous in their use of DHH. This remark applies to Figs 1–4. BMECs, brain microvascular endothelial cells; CD45,
cluster of differentiation 45; CDH5, cadherin5; Cldn5, claudin5; CNS, central nervous system; Ctrl, control; DHH desert
hedgehog; EAE, experimental autoimmune encephalomyelitis; GFAP, glial fibrillary acidic protein; HBMECs, human brain
microvascular endothelial cells; IHH, Indian hedgehog; cam1, intercellular adhesion molecule 1; IL-1β, interleukin 1 beta; MEC,
microvascular endothelial cell; MOG35-55, myelin oligodendrocyte glycoprotein-35-55; NS, non-significant; NG2, neural/glia
antigen 2; qRT-PCR, quantitative reverse transcription polymerase chain reaction; PECAM1, platelet/endothelial cell adhesion
molecule 1; SMA, smooth muscle actin; SHH, Sonic hedgehog; Vcam1, vascular cell adhesion molecule 1; ZO1, zonula occludens
1.
https://doi.org/10.1371/journal.pbio.3000946.g001
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Fig 2. Endothelial-specific Dhh inactivation induces adherens and tight junction down-regulation through stimulation
of FOXO1 transcriptional activity. (A–C) CNS MECs were isolated from DhhECKO and control mice, and (A) Dhh, (B)
Cldn5, and (C) Zo1 expressions were quantified by qRT-PCR. (D–F) Primary BMECs from DhhECKO and control mice were
isolated and cultured on Lab-Tek. (D) CDH5 (in green), (E) ZO1 (in green), and (F) CLDN5 (in red) localizations were
evaluated by immunofluorescent staining of a confluent cell monolayer. Nuclei were stained with DAPI (in blue). The
experiment was repeated 3×. (G–L) CNS MECs were isolated from DhhECKO and control mice, seeded and cultured until
confluency, and (G, H) CDH5, (G, I) ZO1, (G, J) FOXO1, (G, K) and p-FOXO1 expression were quantified by western blot.
(L) BMECs were isolated from DhhECKO mice and control mice, seeded and cultured until confluency and starved for 24 h.
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CTNNβ1 to inhibit transcription factor forkhead box O1 (FOXO1) [27] via PI(3)K–AKT-
dependent phosphorylation, which thereby up-regulates the expression of the endothelial tight
junction protein CLDN5 [27]. Therefore, we next measured the expression level of the phos-
phorylated form of FOXO1 (p-FOXO1) in CNS MEC cultures from DhhECKO and control
(DhhFlox/Flox) mice and demonstrated that p-FOXO1 is down-regulated in DhhECKO mice
compared to controls (Fig 2G, 2J–2K). We then treated CNS MEC cultures from DhhECKO
mice with a cell permeable inhibitor of the transcription factor FOXO1 (AS1842856), which
blocks the transcription activity of FOXO1, and measured Cldn5 mRNA expression. We dem-
onstrated that Cldn5 mRNA expression, in DhhECKO CNS MEC cultures treated with the
inhibitor of FOXO1, returns to the expression level of control CNS MEC cultures, unlike the
DhhECKO CNS MEC cultures treated with DMSO (Fig 2L and S1 Data). Additionally, in
DhhECKO CNS MEC cultures treated with the inhibitor of FOXO1, CLDN5 displays a well-
defined pattern of sharp contours at endothelial cell–cell contacts. In contrast, in DhhECKO
CNS MEC cultures treated with DMSO, a broader, more irregular pattern is detected at endo-
thelial cell–cell contacts (Fig 2M).
We concluded that endothelial autocrine DHH expression at the BBB maintains the pool of
CDH5-CTNNβ1 signaling in endothelial cells, which promotes Cldn5 mRNA expression and
maintains a well-defined CLDN5 pattern of sharp contours at endothelial cell–cell contacts
through the inhibitory phosphorylation of the transcription factor FOXO1 (Fig 2N).
In the white matter, endothelial-specific Dhh inactivation induces BBB
permeability associated with endothelial and astrocytic activation in vivo
In vivo, on spinal cord sections from control and DhhECKO mice, we confirmed that the
expression of adherens junction CDH5 and tight junction CLDN5, when normalized for the
number and length of blood vessels, is down-regulated under resting conditions (Fig 3A–3D,
S1 Data and S3A Fig) and demonstrated that it is associated with an increase accumulation of
serum proteins (fibrinogen (FGB) and albumin (ALB)) [28] (Fig 3B, 3E, 3F, S1 Data, S3B and
S3C Fig) around the vessels, suggesting BBB opening.
We then analyzed the activation status of both the spinal cord endothelium and Glia Limit-
ans in DhhECKO and control littermates. We chose ICAM1 as a marker of endothelial activa-
tion and GFAP as a marker of astrocyte reactivity because they are both widely published in
the context of inflamed CNS tissues and represent a strong indicator of a reactive response of
the CNS endothelium and Glia Limitans.
Using spinal cord sections, we revealed that ICAM1 is up-regulated at the endothelium in
DhhECKO mice compared to littermate controls (Fig 3G, 3I and S1 Data) and associated with a
regionalized up-regulation of GFAP, a marker of astrocyte activation, in white matter (Fig 3H,
3J and S1 Data) but not gray mater (Fig 3H, 3K and S1 Data).
Control BMECs were then treated with DMSO and DhhECKO BMECs with DMSO versus an inhibitor of FOXO1
(AS1842856). (L) CLDN5 expression was then quantified by qRT-PCR and (M) CLDN5 (in red) localization was evaluated
by immunofluorescent staining of a confluent cell monolayer in DhhECKO BMECs treated with DMSO versus an inhibitor of
FOXO1 (AS1842856). Nuclei were stained with DAPI (in blue). The experiment was repeated 3×. (N) Summary outline of
the up-regulation of endothelial junctions by the morphogen DHH through inhibition of FOXO1 transcriptional activity.
�P� 0.05, ��P� 0.01, ���P� 0.001 Mann–Whitney U test. �P� 0.05 Kruskal–Wallis test. The underlying data for Fig 2 can
be found in S1 Data (https://doi.org/10.6084/m9.figshare.12625034.v6). �It is important to note that CNS endothelial cells
are from a pooled source including both brain and spinal cord tissues. Therefore, the resulting cell cultures/lysates may be
heterogeneous in their use of DHH. This remark applies to Figs 1–4. AKT, serine/threonine kinase 1; BMEC, brain
microvascular endothelial cell; CDH5, cadherin5; Cldn5, claudin5; CNS, central nervous system; CTNNβ1, catenin beta 1;
Ctrl, control; DHH desert hedgehog; FOXO1, forkhead box O1; MEC, microvascular endothelial cells; NS, non-significant;
PTCH1, Patched-1; qRT-PCR, quantitative reverse transcription polymerase chain reaction; ZO1, zonula occludens 1.
https://doi.org/10.1371/journal.pbio.3000946.g002
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Fig 3. Endothelial-specific Dhh inactivation induces BBB permeability associated with endothelial and astrocytic
activition in vivo: (A–F) Spinal cord sections were harvested from DhhECKO mice and littermate controls and
immunostained with anti-IB4 (in green), anti-CDH5 (in red or green), anti-CLDN5 (in red), anti-FGB (in red), and
anti-ALB (in red) antibodies. (A) Representative IB4/CDH5 and (B) CDH5/FGB staining are shown. (C) CDH5/IB4,
(D) CLDN5/IB4, (E) FGB, and (F) ALB positive areas were quantified (DhhECKO n = 6 to 12, WT n = 6 to 11). (G–K)
Spinal cord sections were harvested from DhhECKO mice and littermate controls and immunostained with anti
PECAM1 (in red), anti-ICAM1 (in green), and anti-GFAP (in gray) antibodies. (G, H) Representative PECAM1,
ICAM1, and GFAP staining are shown. (H) GFAP staining regionalization (WM and GM) is highlighted by orange
dotted lines on the images. (I) ICAM1 and (J, K) GFAP positive areas in the WM (J) and GM (K) were quantified
(DhhECKO n = 8 to 13, WT n = 5 to 12). �P� 0.05, ��P� 0.01, ���P� 0.001, ����P� 0.0001 Mann–Whitney U test.
The underlying data for Fig 3 can be found in S1 Data (https://doi.org/10.6084/m9.figshare.12625034.v6). �It is
important to note that CNS endothelial cells are from a pooled source including both brain and spinal cord tissues.
Therefore, the resulting cell cultures/lysates may be heterogeneous in their use of DHH. This remark applies to Figs 1–
4. ALB, albumin; AU, arbitrary units; BBB, blood–brain barrier; CDH5, cadherin5; Cldn5, claudin5; Ctrl, control;
DHH desert hedgehog; FGB, fibrinogen; GFAP, glial fibrillary acidic protein; GM, gray matter; IB4, isolectin B4;
ICAM1, intercellular adhesion molecule 1; NS, non-significant; PECAM1, platelet/endothelial cell adhesion molecule
1; WM, white matter; WT, wild type.
https://doi.org/10.1371/journal.pbio.3000946.g003
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Here, we detected that, in the white matter, DHH expression at the endothelium controls
BBB tightness and demonstrated that endothelial-specific Dhh inactivation at the BBB drives
endothelial and astrocyte activation.
DhhECKO-induced BBB breakdown is sufficient to induce a secondary CNS
protective barrier at the Glia Limitans
As we already demonstrated in Fig 3, DhhECKO mice display BBB leakage, whereas control lit-
termates feature a tight BBB.
Although we demonstrated BBB leakage in DhhECKO mice (Fig 3B, 3E, 3F and S1 Data), we
noticed that infiltrating plasmatic proteins are concentrated around the vascular area in arteri-
oles and venules and not seamlessly distributed within the parenchyma��. To verify this obser-
vation, we quantified the distribution of immunoglobulin G (IgG) and a smaller sized dye (70
kDa fluorescein isothiocyanate (FITC) Dextran) in the 3 compartments (lumen, PVS, and
parenchyma). Specifically, in control mice, there is no significant endothelial permeability,
with more than 95% of IgG and 97% of 70 kDa FITC Dextran contained in the lumen of blood
vessels and 5% of IgG and 3% of 70 kDa FITC Dextran segregated in the PVS area limited by
the astrocytic end feet (aquaporin 4 (AQP4) or laminin (LAM) antigen) on 1 side and the ves-
sel wall (PECAM1 or LAM antigen) on the other side, and none found in the parenchyma (S1
Data, S4A–S4E Fig and S2 Data). The quantification protocol of IgG and 70 kDa FITC Dextran
distribution within the lumen, PVS, and parenchyma is described in S4 Fig. In DhhECKO mice,
vascular leakage is significant, but strikingly, 50% of IgG and 50% of 70 kDa FITC Dextran is
contained into the PVS, while none is found in the parenchyma, indicating the presence of a
secondary barrier at the Glia Limitans (S1 Data, S4A–S4E Fig and S2 Data). Interestingly,
some overlap is observed between the IgG signal and the AQP4 signal, concentrated within the
internal surface of the Glia Limitans (Fig 4A). Thus might reflect a potential interaction
between the inner face of astrocyte end feet and IgG accumulated in the PVS, as astrocytes
express Fc receptors (cell surface receptors for IgG), which play a role in both CNS health and
disease [29,30]. The perivascular trapping of IgG in DhhECKO mouse CNS was confirmed
using co-immunostaining of IgG and LAM antigen, which mark the endothelial and astrocytic
basement membranes (S5A and S5B Fig).
We have previously found that reactive astrocytes express tight junctions, notably CLDN4,
under inflammatory conditions in a mouse model of multiple sclerosis (EAE) [26]. Here, we
found that these data are relevant to human disease since CLDN4 is also expressed by reactive
astrocytes, with stronger CLDN4 labeling intensity at the Glia Limitans, in active cortical
lesions from multiple sclerosis patients (Fig 4D). Based on the above results, we investigated
whether the PVS entrapment of plasmatic proteins observed in DhhECKO mice is linked to the
expression of the tight junction CLDN4 at the Glia Limitans in response to BBB permeability
(Fig 4E–4H and S1 Data). We showed that CLDN4 is expressed at the Glia Limitans in
DhhECKO mice but not control littermates (Fig 4E–4H and S1 Data) using isolated neurovascu-
lar enriched fractions. Small intestine samples were used as a positive control for the quantifi-
cation of CLDN4 by western blot (S6A Fig).
Altogether, these results suggest that, in DhhECKO mice, spontaneous BBB permeability leads
to the establishment of a physical barrier at the Glia Limitans, characterized by the expression of
the tight junction protein CLDN4. Therefore, in DhhECKO mice, astrocytic end feet at the Glia
Limitans are “preconditioned” to form a secondary barrier protecting the parenchyma. (��It is
important to note that this study focuses on arterioles and venules but not capillaries. Indeed,
CLDN4 is only up-regulated in DhhECKO-enriched neurovascular fractions, which are 100 μm
and larger in diameter (Fig 4F–4H and S1 Data). In the lysates obtained with enriched
PLOS BIOLOGY Blood brain barrier disruption leads to astrocyte barrier formation
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Fig 4. DhhECKO-induced BBB breakdown is sufficient to induce a secondary CNS protective barrier at the Glia
Limitans. (A–C) Spinal cord sections were harvested from DhhECKO mice and littermate controls and (A) immunostained
with anti-PECAM1 (in gray), anti-AQP4 (in green), and anti-IgG (in red) antibodies (nuclei were stained with DAPI (in
blue)), and (B, C) the distribution of IgG within the lumen, PVS, and parenchyma was quantified. We quantified the
amount of IgG in the PVS and parenchyma and inferred from it the amount of IgG contained in the lumen. (DhhECKO
n = 6, WT n = 6). P< 0.0001, 95% CI: 0.3281 to 0.5558, chi-squared test. (D) Human active multiple sclerosis cortical
lesions were obtained from the NeuroCEB biobank and immunostained with anti-ZO1 (in gray), anti-GFAP (in red), and
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neurovascular fractions, which are 20 μm and larger, CLDN4 expression level is not different
between the DhhECKO and control group (S6B–S6D Fig and S2 Data). In this condition,
CLDN4 expression in arterioles and venules might have been lost in the crowd of capillaries.)
Endothelial signals can drive astrocyte barrier properties at the Glia Limitans
Given the above results, we wanted to determine if astrocyte barrier formation requires signals
from the endothelial BBB or from the plasmatic protein perivascular infiltrate. To do so, we
first studied in vitro the response of normal human astrocytes (NHAs) to HBMEC conditioned
media versus plasmatic proteins from healthy donors. HBMECs used to produce the condi-
tioned media were treated with either the osmotic agent Mannitol or the pro-permeability fac-
tor vascular endothelial growth factor A (VEGFA) to induce BBB breakdown (S7A Fig and S2
Data) through various methods.
We demonstrated that Gfap (Fig 5A, 5E–5I and S1 Data), aldehyde dehydrogenase 1 family,
member l1 (Aldh1l1) (Fig 5B and S1 Data) (markers of astrocyte reactivity), and Cldn4 mRNA
expression (Fig 5D, 5A–5H, 5J and S1 Data) are up-regulated in the NHA treated with
HBMEC-conditioned media but not in the NHA treated with plasma from healthy donors.
vimentin (Vim) (marker of astrocyte reactivity) mRNA expression level was not modulated in
any condition (Fig 5C and S1 Data).
To confirm this observation in vivo, we delivered murine VEGFA or murine plasmatic pro-
teins into the left cerebral cortex of adult mice and evaluated the consequences on CLDN4
expression by astrocytes. PBS stereotactic administration was used as a control. Importantly,
VEGFA cortical stereotactic injection has already been shown to efficiently induce BBB break-
down in mice [17,31].
In vivo, GFAP (Fig 5K–5N and S1 Data) and CLDN4 (Fig 5K–5M, 5O and S1 Data) are
induced in mouse cortex after murine VEGFA and murine plasmatic protein treatments, with
VEGFA having a much stronger effect than plasmatic proteins.
We concluded that permeable endothelial monolayers produce signals that can drive astro-
cyte reactivity and tight junction expression. Plasmatic protein involvement in controlling
astrocyte barrier behavior is, however, less clear as astrocyte reactivity and tight junction
expression are up-regulated in vivo but not in vitro when treated with plasma; further investi-
gations will be necessary to identify the mechanisms involved.
Mice with endothelial Dhh inactivation display reduced disability in a
model of multiple sclerosis during the onset of the disease
To examine the impact of these findings on disease severity, we investigated the phenotype of
induced experimental multiple sclerosis (EAE) in DhhECKO and control mice.
anti-CLDN4 (in green) antibodies. Strong CLDN4 signal at the Glia Limitans is indicated by white arrows. Nuclei were
stained with DAPI (in blue). (E–H) Enriched neurovascular fractions were isolated from DhhECKO and control mouse
CNS and (E) immunostained with anti-CDH5 (in gray), anti-CLDN4 (in red), and anti-GFAP (in green) antibodies
(nuclei were stained with DAPI (in blue)). (F) Representative blots of GFAP and CLDN4 expression levels on DhhECKO
and control mouse enriched neurovascular fractions were shown, and (G, H) GFAP and CLDN4 expression levels were
quantified by western blot of DhhECKO and control mouse enriched neurovascular fractions. (DhhECKO n = 5, WT n = 5).
��P� 0.01, Mann–Whitney U test. The underlying data for Fig 4 can be found in S1 Data (https://doi.org/10.6084/m9.
figshare.12625034.v6). �It is important to note that CNS endothelial cells are from a pooled source including both brain
and spinal cord tissues. Therefore, the resulting cell cultures/lysates may be heterogeneous in their use of DHH. This
remark applies to Figs 1–4. AQP4, aquaporin 4; BBB, blood–brain barrier; CDH5, cadherin5; CI, confidence interval;
CLDN4, Claudin4; CNS, central nervous system; Ctrl, control; DHH desert hedgehog; GFAP, glial fibrillary acidic protein;
IgG, immunoglobulin G; NS, non-significant; PECAM1, platelet/endothelial cell adhesion molecule 1; PVS, perivascular
space; WT, wild type; ZO1, zonula occludens 1.
https://doi.org/10.1371/journal.pbio.3000946.g004
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Fig 5. Endothelial signals can drive astrocyte barrier properties at the Glia Limitans. (A–K) NHA were cultured until
confluency and starved for 24 h. NHA were then treated for 24 h with HBMEC medium from untreated cells (control
condition), conditioned media from HBMECs treated with VEGFA, conditioned media from HBMECs treated with
Mannitol, or HBMEC medium with 20% plasma from healthy donors (Mannitol and VEGFA were washed out of the
HBMEC cultures before the medium was used to treat the NHA cultures). (A) Gfap, (B) Aldh1l1, (C) Vim, and (D) Cldn4
mRNA expression was quantified by qRT-PCR. (Post-VEGFA n = 5, Mannitol n = 8 to 9, Plasma n = 7 to 8, Vehicle
control n = 14 to 15). (E–H) GFAP (in green) and (E) CLDN4 (in red) localizations were evaluated by immunofluorescent
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We observed that in control mice, neurologic deficits were observed from day 9 and
increased in severity until day 18, when clinical score stabilized at a mean of 3.2, representing
hind limb paralysis. In contrast, the onset of clinical signs in DhhECKO mice was first seen 4
days later, and the clinical course was much milder. In DhhECKO mice, disease reached a pla-
teau at day 21 at a mean of 2.3, indicating hind limb weakness and unsteady gait, a mild pheno-
type (Fig 6A and S1 Data). The EAE peak score (Fig 6B and S1 Data) and average score during
the time of disability (Fig 6C and S1 Data) were both decreased in DhhECKO mice, but there
were no significant changes in survival and mortality rates (Fig 6D and S1 Data).
Interestingly, the reduced clinical course of EAE in DhhECKO mice was much more marked
during the onset of the disease (between day 12 and day 20 post EAE induction). However,
when the plateau phase was reached (after day 21 post EAE induction), the clinical score differ-
ence between the DhhECKO and the control group was greatly reduced and coincided with an
acceleration of the mortality rate in both groups (Fig 6A–6D and S1 Data). One explanation
for this observation is that, in the DhhECKO group, inflammatory cells, accumulated in the
PVS, end up degrading astrocytic tight junctions by secreting proteases. This previously
described phenomenon [26] explains how inflammatory cells trapped in the PVS can eventu-
ally pass through the astrocytic barrier at the Glia Limitans and thereby enter the CNS, thus
inactivating Dhh at the BBB. This in turn slows disease progression until the perivascular accu-
mulation of inflammatory cells causes the degradation of the astrocyte secondary barrier, lead-
ing to the deterioration of the clinical course of EAE in the DhhECKO mice.
Importantly, the clinical course in the DhhECKO mice is correlated with strikingly decreased
areas of demyelination as compared to the control cohort (Fig 6E, 6F and S1 Data). Critically,
these studies reveal that the clinical course and pathology of EAE are strongly reduced in
DhhECKO mice during the onset of the disease.
We concluded that endothelial Dhh knockdown-induced BBB opening is associated with a
clinical protective effect during the onset of the disease in a model of multiple sclerosis.
Mice with endothelial Dhh inactivation display a reinforced barrier at the
Glia Limitans, restraining access to the parenchyma to inflammatory
infiltrate in a model of multiple sclerosis
Although DhhECKO mice display equivalent FGB densities (Fig 7A and S1 Data) as well as
numbers of CD45+ leukocytes (Fig 7B and S1 Data) in lesions compared to those in control
mice, neuropathology in both cohorts appeared very different.
We found that while the BBB is permeable in both groups, with plasmatic protein extravasa-
tion associated with equivalent CDH5 densities, astrocyte reactivity in EAE lesions in
DhhECKO mice is greatly increased with GFAP immunoreactivity strongest at the Glia Limitans
(Fig 7C, 7E and S1 Data). Moreover, infiltrating plasmatic proteins in DhhECKO mice show less
CNS parenchymal dispersion (Fig 7E, 7F and S1 Data), with 68.0% of FGB trapped into the
staining of a confluent NHA monolayer. Nuclei were stained with DAPI (in blue). The experiment was repeated 3 times. (I,
J) GFAP and CLDN4 positive areas were then quantified. (Post-VEGFA n = 7 to 8, Mannitol n = 7 to 8, Plasma n = 8,
Vehicle control n = 7 to 8). (K–O) Cerebral cortices of 10-week-old C57BL/6 mice were harvested 24 h following
stereotactic microinjection of murine VEGFA (60 ng in 3 μL PBS), healthy C57BL/6 mouse plasma (3 μL), or vehicle
control (3 μL PBS). (K–M) Cortical lesions were immunostained with anti-GFAP and anti-CLDN4 antibodies. (N) GFAP
positive areas and (O) CLDN4 positive areas were quantified (VEGFA n = 4, healthy C57BL/6 mouse plasma n = 4, Vehicle
control n = 4). �P� 0.05, ��P� 0.01, ���P� 0.001 Kruskal–Wallis test. The underlying data for Fig 5 can be found in S1
Data (https://doi.org/10.6084/m9.figshare.12625034.v6). Aldh1l1, aldehyde dehydrogenase 1 family, member l1; AU,
arbitrary units; CLDN4, Claudin4; Ctrl, control; GFAP, glial fibrillary acidic protein; HBMEC, human brain microvascular
endothelial cells; NHA, normal human astrocytes; NS, non-significant; qRT-PCR, quantitative reverse transcription
polymerase chain reaction; VEGFA, vascular endothelial growth factor A; Vim, vimentin.
https://doi.org/10.1371/journal.pbio.3000946.g005
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Glia Limitans in the DhhECKO cohort versus 32% in the control cohort (Fig 7F, S7B Fig and S1
Data).
In previous work from our laboratory [8], we showed that endothelial-specific deletion of
Dhh in the peripheral vasculature is associated with vascular permeability and endothelial acti-
vation, notably in the lung, and that lipopolysaccharide (LPS) injection increased pulmonary
neutrophil infiltration in DhhECKO mice compared to control littermates. Therefore, we can
hypothesize that endothelial Dhh knockdown increases the peripheral recruitment and activa-
tion of inflammatory cells that need to travel to the CNS. However, in our study, we do not
Fig 6. DhhECKO mice display reduced disability in a model of multiple sclerosis during the onset of the disease.
(A) DhhECKO and control mice induced with EAE were scored daily on a standard 5-point scale, nonlinear regression
(Boltzmann sigmoidal). (DhhECKO n = 8, WT n = 10). (B) DhhECKO and control mice EAE peak score, (C) EAE
average score during time of disability, and (D) mortality rate were quantified other the course of the disease. (E, F)
Spinal cord EAE lesions from DhhECKO mice and littermate controls were harvested at 28 days post induction or at the
time of euthanasia. (E) DhhECKO and control lesions were immunostained with an anti-MBP (in green) antibody;
arrows indicate white matter loss areas. Nuclei were stained with DAPI (in blue). (F) MBP positive areas were
quantified ((DhhECKO n = 5, WT n = 5). �P� 0.01, Mann–Whitney U test. The underlying data for Fig 6 can be found
in S1 Data (https://doi.org/10.6084/m9.figshare.12625034.v6). AU, arbitrary units; Ctrl, control; DHH desert
hedgehog; EAE, experimental autoimmune encephalomyelitis; MBP, myelin basic protein; NS, non-significant; WT,
wild type.
https://doi.org/10.1371/journal.pbio.3000946.g006
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Fig 7. Mice with endothelial Dhh knockdown display a reinforced barrier at the Glia Limitans restraining access to
the parenchyma to inflammation in a model of multiple sclerosis. (A–H) Spinal cord from DhhECKO mice and
littermate controls under resting condition and after EAE induction were harvested. (A–D) DhhECKO and control sections
were immunostained with anti-FGB, anti-CD45, anti-GFAP, anti-IB4, and anti-CDH5 antibodies. (A) FGB positive areas,
(B) the number of CD45+ T cells per mm2, (C) GFAP positive areas, and (D) CDH5/IB4 positive area were quantified
(DhhECKO n = 5 to 17, WT n = 5 to 10). (E) DhhECKO and control EAE lesions were immunostained with anti-CDH5 (in
gray), anti-FGB (in green), and anti-GFAP (in red) antibodies (Nuclei were stained with DAPI (in blue)), and (F) the
PLOS BIOLOGY Blood brain barrier disruption leads to astrocyte barrier formation
PLOS Biology | https://doi.org/10.1371/journal.pbio.3000946 November 30, 2020 15 / 30
observe any difference in terms of CD45+ leukocyte populations in the spinal cord of DhhECKO
and control mice induced with EAE MOG35-55. What we do observe is a significant difference
in terms of the repartition of these CD45+ cell populations between both groups, with 77.1%
of CD45+ cells trapped into the PVS in the DhhECKO cohort versus 25.1% in the control cohort
(Fig 7G, 7H, S1 Data and S7C Fig).
Altogether, these data suggest less access through the Glia Limitans in the DhhECKO mice
compared to the littermate control mice. Finally, we demonstrated that CLDN4 expression in
spinal cord EAE lesion lysates is up-regulated in DhhECKO mice as compared to control mice
(Fig 7I, 7J and S1 Data).
Collectively, data from Fig 4 to Fig 7 reveal that conditional loss of a key structural compo-
nent of endothelial integrity at the BBB in DhhECKO mice leads to increased astrocyte reactivity
and implementation of barrier properties at the Glia Limitans, allowing for less diffusion of
plasmatic proteins and immune cells into the CNS parenchyma than in control mice. There-
fore, in DhhECKO mice, astrocytic end feet at the Glia Limitans are “preconditioned” to form a
barrier, explaining their ability to protect the parenchyma more efficiently during neuropa-
thology than in controls, leading to the protective effect observed clinically. Thus, we identify
BBB leakage, induced by the down-regulation of Dhh endothelial expression, as an important
mechanism controlling Glia Limitans reactivity and barrier properties, and subsequently, tis-
sue damage and clinical deficits in a model of human disease (Fig 8).
Discussion
While it is now well established that BBB breakdown leads to soluble factor and inflammatory
cell infiltration into the PVS during neuropathology [4], the function of the Glia Limitans bar-
rier is just starting to be unraveled [15,20,24,26]. In the present study, we have enabled a differ-
ent perspective on CNS barrier organization, unveiling the existence of 2 independent,
dissociable states of the astrocyte and endothelial barriers in the neurovascular unit. Indeed,
we confirmed that, just like the BBB, the Glia Limitans can form a protective barrier. For the
first time, to our knowledge, we have demonstrated that BBB breakdown is sufficient to induce
chronic barrier properties at the Glia Limitans, and we uncovered crosstalk from endothelial
cells to astrocytes that restricts access to the parenchyma of plasmatic proteins and inflamma-
tory cells during multiple sclerosis. Moreover, we showed that in DhhECKO mice, which display
an open BBB, astrocytes express the tight junction protein CLDN4 under resting conditions.
Therefore, under neuroinflammatory conditions, Glia Limitans in DhhECKO mice is primed
with stronger barrier properties protecting against the onset and severity of EAE symptoms in
the DhhECKO mice compared to control littermates.
However, 2 questions remain regarding barrier properties at the Glia Limitans: (1) Is this a
specific aspect of the DhhECKO mouse model or more broadly applicable to any model of BBB
breakdown; and (2) is it observed in other CNS pathologies than inflammation?
distribution of FGB within the Glia Limitans and the parenchyma was quantified. (DhhECKO n = 6, WT n = 5). P< 0.0001,
95% CI: 0.2467 to 0.5137, chi-squared test. (G) DhhECKO and control lesions were immunostained with anti-LAM (in red)
and anti-CD45 (in green) antibodies (Nuclei were stained with DAPI (in blue)), and (H) the distribution of CD45+ T
lymphocytes within the Glia Limitans and the parenchyma was quantified. P< 0.0001, 95% CI: 0.4107 to 0.6581, chi-
squared test. (I) Representative blots of CLDN4 expression level on DhhECKO and control spinal cord EAE lesion lysates
were shown, and (J) CLDN4 expression level was quantified by western blot on DhhECKO and control spinal cord EAE
lesion lysates. (DhhECKO n = 5, WT n = 5). ��P� 0.01, Mann–Whitney U test. �P� 0.05, ��P� 0.01, Kruskal–Wallis test.
The underlying data for Fig 7 can be found in S1 Data (https://doi.org/10.6084/m9.figshare.12625034.v6). AU, arbitrary
units; CD45, cluster of differentiation 45; CDH5, cadherin 5; CI, confidence interval; CLDN4, Claudin4; Ctrl, control;
DHH desert hedgehog; EAE, experimental autoimmune encephalomyelitis; FGB, fibrinogen; GFAP, glial fibrillary acidic
protein; IB4, isolectin B4; LAM, laminin; NS, non-significant; PVS, perivascular space; WT, wild type.
https://doi.org/10.1371/journal.pbio.3000946.g007
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Fig 8. Schematic of the BBB and Glia Limitans in DhhECKO versus control mice, in health and inflammatory disease.
Under resting conditions, in control mice, ECs express CLDN5 and CDH5, which reinforce a closed BBB. In DhhECKO mice,
CLDN5 and CDH5 are disrupted leading to BBB permeability; in turn, astrocytes of the Glia Limitans up-regulate CLDN4,
closing the Glia Limitans and restricting incoming plasmatic proteins to the PVS. Under inflammatory condition, in both
control and DhhECKO mice, CLDN5 and CDH5 are disrupted leading to BBB permeability, astrocyte reactivity, and up-
regulation of CLDN4. However, in DhhECKO mice, astrocytic end feet of the Glia Limitans have been “preconditioned” to
form a barrier, explaining their ability to trap plasmatic proteins and inflammatory cells in the PVS, and thus protecting the
parenchyma more efficiently than in the controls. BBB, blood–brain barrier; CDH5, cadherin 5; CLDN4, Claudin4; CLDN5,
claudin5; CTNNβ1, catenin β1; DHH desert hedgehog; EC, endothelial cells; FOXO1, forkhead box O1; PTCH1, Patched-1;
PVS, perivascular space.
https://doi.org/10.1371/journal.pbio.3000946.g008
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A model of pericyte-deficient mice featuring BBB breakdown has been described; but, in
this model, endothelial permeability is due to increased transcytosis and not junction degrada-
tion as in the DhhECKO mouse model. Therefore, it would be interesting to study the behavior
of astrocytes in this model, notably their capacity to express CLDN4 and to restrain parenchy-
mal access to plasmatic proteins. Should astrocyte barrier properties be observed in the peri-
cyte-deficient mouse model, thus would be suggestive for a more generalized role of BBB
breakdown in driving astrocyte barrier properties, either by parallel or convergent mechanisms.
The expression of CLDN4 by astrocytes has only been identified in mouse models of CNS
inflammation (acute CNS inflammation model (stereotactic injection of the pro-inflammatory
cytokine IL-1β and model of multiple sclerosis: EAE MOG35-55) [26]. However, in the present
study, we demonstrated that CLDN4 is expressed by astrocytes under resting conditions in
response to BBB opening in the DhhECKO mouse model and after cortical stereotactic injection
of the pro-permeability factor VEGFA. The next step would be to examine astrocytic CLDN4
expression in other pathologies of the CNS, notably Alzheimer’s disease, stroke, or amyotro-
phic lateral sclerosis in which BBB permeability has been identified as a critical pathophysio-
logical player. This could implicate CLDN4-mediated barrier function in astrocytes as a more
generalized defense against BBB opening in other chronic diseases of the CNS.
The critical role of Hh signaling in CNS neuroinflammation was first highlighted in 2011;
this study revealed that during EAE, the morphogen SHH is expressed by reactive astrocytes
and participates in the maintenance of BBB integrity [4]. Following this discovery, our group
found that DHH is physiologically expressed at the BBB in adults [8]. Here, we demonstrated
for the first time that DHH is down-regulated at the BBB during EAE and that DHH knock-
down is sufficient to induce BBB permeability by inhibiting CDH5 and CLDN5 expression
through the modulation of FOXO1 activity, strengthening the idea that HH signaling is essen-
tial to control BBB integrity both physiologically and under multiple sclerosis conditions.
Based on our results and the literature, we hypothesize that DHH is necessary to maintain BBB
tightness under physiological conditions and that DHH down-regulation under inflammatory
conditions might be offset by astrocytic SHH secretion to maintain BBB homeostasis during
disease progression.
Over the past years, the field has begun to acknowledge the fact that the BBB is not the sole
line of defense of the CNS and that the astrocytic end feet of the Glia Limitans might play a
role in restricting access to the parenchyma. Indeed, it was first described that in spinal cord
injury, astrocyte scar borders corral inflammatory cells within areas of damaged tissue [32,33].
Moreover, we have found that during EAE, reactive astrocytes of the Glia Limitans form tight
junctions of their own containing CLDN4 [26], a junction protein also expressed in tightly
sealed epithelia [34,35]. Noteworthy is the fact that down-regulation or reorganization of
CLDNs and other tight junction proteins has been implicated in permeability in various tis-
sues, particularly the gut [19,36,37]; however, reports of dynamic tight junction protein induc-
tion resulting in functional barrier formation have been rare [38,39]. Here, we have shown for
the first time that genetically induced disruption of endothelial junctions is sufficient to induce
CLDN4 expression at the Glia Limitans under resting condition, identifying an inducible
astrocyte barrier mediated fully by signals transmitted by the open BBB.
It has already been described, by our group and others, that astrocytes can send signals,
notably VEGFA [18], thymidine phosphorylase (TYMP) [17], and SHH [4], to the BBB to
modulate its state (tight versus permeable). In this study, we identify a reciprocal signaling
pathway demonstrating that BBB endothelial junction disruption leads to CLDN4 expression
at the Glia Limitans. Interestingly, endothelial cell capacity to send signals to neighboring cells
has been previously identified, notably in the context of pericyte (mural cells associated with
arterioles, capillaries, and venules) recruitment at the vascular wall [40]. Specifically, it has
PLOS BIOLOGY Blood brain barrier disruption leads to astrocyte barrier formation
PLOS Biology | https://doi.org/10.1371/journal.pbio.3000946 November 30, 2020 18 / 30
been shown that platelet-derived growth factor subunit b (PDGFB) is secreted from angiogenic
sprout endothelium where it serves as an attractant for co-migrating pericytes, which in turn
express platelet-derived growth factor receptor beta (PDGFRβ) [41]. Based on these arguments
and our results, it appears highly likely that endothelial signals can be sent to astrocytes. Identi-
fying such signals will be the aim of future studies by our group.
We then showed that in animals, which exhibit an open BBB (DhhECKO mice), astrocytic
end feet of the Glia Limitans form a barrier more efficiently than in the littermate controls,
leading to the protective effect observed clinically in the model of multiple sclerosis. This is
somehow reminiscent of what is observed in brain ischemic preconditioning where a mild
nonlethal ischemic episode (preconditioning) can produce resistance to a subsequent more
severe ischemic insult [42,43]. Here, inducing BBB opening and PVS plasmatic protein accu-
mulation produces resistance to the subsequent massive inflammatory infiltration induced by
multiple sclerosis development. This could account for the infrequency of recurrent multiple
sclerosis relapse/lesion formation at the same location in the CNS. Interestingly, among neu-
rons and nonneuronal cells, astrocytes are considered increasingly important in regulating
cerebral ischemic tolerance [44], and a parallel can be easily drawn between these results and
ours showing a major role for “preconditioned” astrocytes in the control of “chronic neuroin-
flammation tolerance” and protection against further relapse.
In light of the above observations, we may assume that the CNS has the ability to protect
itself against isolated BBB leakage episodes through a secondary barrier at the Glia Limitans
that takes over once the BBB is open. Moreover, it suggests that manipulation of the BBB and
Glia Limitans in combination may have greater potential than either alone to control CNS
entry of leukocytes and pro-inflammatory soluble factors in conditions such as multiple sclero-
sis and perhaps more widely. Indeed, taking into account both components of the neurovascu-
lar unit is of translational interest, notably to limit CNS parenchymal access to pathogenic
agents by strengthening the Glia Limitans once the BBB is open in cardiovascular diseases
such as brain ischemic strokes [45], neuroinfections [46], and neurodegeneration (Parkinson/
Alzheimer’s diseases and vascular dementia) [47], or to facilitate parenchymal access to drugs,
by opening the BBB and Glia Limitans together, in CNS tumor treatment [48]. Along similar
lines, it is unknown how the barrier properties of the Glia Limitans may impact the pharmaco-
kinetics of drugs that must enter the CNS parenchyma in conditions such as multiple sclerosis,
which may account for treatment failure.
In summary, our study first demonstrates the critical role of DHH in maintaining BBB
integrity. We find that DHH is down-regulated during the animal model of multiple sclerosis
and that Dhh knockdown leads to BBB opening. Using Dhh knockdown as a tool to cause BBB
opening, we then show that BBB permeability is sufficient to induce a secondary barrier at the
Glia Limitans, mediated by CLDN4 and astrocyte reactivity. These findings not only highlight
the capacity for bidirectional signaling between the endothelial BBB and the astrocytic Glia
Limitans in modulating the double barriers of the CNS but also provide support for a novel
concept of “chronic neuroinflammatory tolerance”, in which chronic induction of Glia Limit-
ans barrier properties by BBB opening may lead to a protective effect against neuroinflamma-
tory disease activity and progression.
Methods
Human tissues
Cortical sections from multiple sclerosis patients (active lesions) and healthy controls (frontal
cortex) were obtained from the NeuroCEB bio bank (https://www.neuroceb.org/fr). The sec-
tions were 30 μm thick and obtained from fresh frozen samples.
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Mice
Dhh Floxed (DhhFlox) mice were generated at the “Institut Clinique de la Souris” through the
International Mouse Phenotyping Consortium (IMPC) from a vector generated by the Euro-
pean conditional mice mutagenesis program, EUCOMM, and described before [8].
The Cre recombinase in cadherin5 (Cdh5)-CreERT2 mice was activated by intraperitoneal
injection of 1-mg tamoxifen (Sigma Aldrich, St. Louis, Missouri, United States of America) for
5 consecutive days at 8 weeks of age. Mice were phenotyped 2 weeks later. Successful and spe-
cific activation of the Cre recombinase has been verified by measuring recombination efficacy
in Cdh5-CreERT2;Rosa26mTmG mice (S2A Fig). Importantly, Dhh endothelial knockdown does
not impact CNS angiogenesis (S2 Data) nor angioarchitecture (S2D Fig). The Cdh5-CreERT2
mice and C57BL/6 mice were purchased from Jackson Laboratories (Bar Harbor, Maine,
USA).
Ethical statement
Human samples: The NeuroCEB bio bank and the INSERM U1034 certify that all human sec-
tions utilized for this study are ethically obtained with documented, legal permission for
research use (authorization number #AC-2018-3290 obtained from the Ministry of Higher
Education and Research) and in the respect of the written given consent from the source per-
son in accordance with applicable laws and the World Medical Association (WMA) Helsinki
declaration of 2013.
Animal experiments were performed in accordance with the guidelines from Directive
2010/63/EU of the European Parliament on the protection of animals used for scientific pur-
poses and approved by the local Animal Care and Use Committee of the Bordeaux University
CEEA50 (IACUC protocol #16901).
Neurovascular fraction enrichment from mouse CNS
Mouse was humanely killed by cervical dislocation, and its head was cut and rinsed with 70%
ethanol. Brain and spinal cord were then harvested, and cerebellum, olfactory bulb, and white
matter were removed from the brain with sterile forceps. Additionally, meninges were elimi-
nated by rolling a sterile cotton swab at the surface of the cortex. The cortex and spinal cord
were then transferred in a potter containing 2 mL of buffer A (HBSS 1X w/o phenol red
(Gibco, Waltham, Massachusetts, USA), 10-mM HEPES (Gibco), and 0.1% bovine serum
albumin (BSA) (Sigma Aldrich), and the CNS tissue was pounded to obtain an homogenate,
which was collected in a 15-mL tube. The potter was rinsed with 1 mL of buffer A, which was
added to the 2-mL homogenate. Cold 30% dextran solution was then added to the tube (V:V)
to obtain a 15% dextran working solution centrifuged for 25 minutes at 3,000 g, 4˚C without
brakes. After centrifugation, the pellet (neurovascular components and red cells) was collected,
and the supernatant (dextran solution and neural components) was centrifuged again to get
the residual vessels. Neurovascular components were then pooled and resuspended in 4 mL of
buffer B (HBSS 1X Ca2+/ Mg2+ free with phenol red (Gibco), 10-mM HEPES (Gibco), and
0.1% BSA (Sigma Aldrich)).
Neurovascular fraction enrichment for RT-PCR, western blots, or
immunohistochemistry
After centrifugation of the cell suspension, the pellet was washed 3 times with the buffer B and
filtered through a 100-μm nylon mesh (Millipore Corporation, Burlington, Massachussetts,
USA). The nylon mesh was washed with 7 mL of buffer B to collect the retained enriched
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neurovascular fractions. The suspension was then centrifuged for 10 minutes at 1,000 g, and
the pellet suspended in 300 μL of radioimmunoprecipitation assay (RIPA) lysis buffer for west-
ern blot analysis or 1,000 μL of Tri-Reagent (MRC, Cincinnati, Ohio, USA) for quantitative
reverse transcription polymerase chain reaction (qRT-PCR) analysis. For immunohistochem-
istry, the pellet was suspended in 3 mL of a solution of matrigel (Corning, Steuben, New York,
USA)-Dulbecco’s Modified Eagle Medium (DMEM) 1 g/L glucose, Mg+, Ca2+ (Gibco) 1:80,
distributed on a labtek (Starstedt, Nümbrecht, Germany) (1 mouse brain is needed to seed 1
labtek) and incubated for 30 minutes at 37˚C. Finally, the enriched neurovascular fraction
embedded in the matrigel (Corning) solution was fixed with 10% formalin for 10 minutes.
Primary culture of mouse CNS micro vascular endothelial cells (CNS MECs)
After centrifugation of the cell suspension, the pellet was washed 3 times with the buffer B and
transferred in an enzyme solution (2 mg/mL Collagenase/Dispase (Roche, Bale, Switzerland),
0.147 μg/mL TLCK (Lonza, Bäle, Switzerland), and 10 μg/mL DNAse 1 (Roche)), prewarmed
at 37˚C, before being placed on a shaking table at maximum speed agitation at 37˚C. After 30
minutes, the digestion was stopped by adding 10 mL of buffer B, the cell suspension centri-
fuged, and the digested neurovascular pellet washed 3 times with 3 mL of buffer B. After the 3
washing steps, the digested neurovascular pellet was resuspended in 1 mL of Mouse Brain
Endothelial Cell Culture Medium (DMEM 1 g/L glucose, Mg+, Ca2+ (Gibco), fetal bovine
serum (FBS) 20% (Gibco), sodium pyruvate 2% (Gibco), nonessential amino acids 2%
(Lonza), FGF 1 ng/mL (PeproTech, Rocky Hill, New Jersey, USA), and gentamycin 10 mg/mL
(Gibco)), and plated on a labtek (Starstedt) (1 mouse brain is needed to seed 1 labtek) previ-
ously coated with 2% matrigel (Corning) diluted in DMEM 1 g/L glucose, Mg+, Ca2+ (Gibco).
Cell culture
HBMECs (Alphabioregen–CliniSciences, Nanterre, France) were cultured in endothelial basal
medium-2 (EBM-2) supplemented with EGM-2 BulletKits (Lonza). Cells from passage 3 to
passage 6 were used. Before any treatment, cells were serum starved in 0.5% FBS EGM-2
medium for 24 hours. NHAs (Lonza) were cultured in astrocyte basal medium (ABM) supple-
mented with AGM BulletKits (Lonza). Cells from passage 2 to passage 4 were used. Before any
treatment, cells were serum starved in DMEM 1 g/L glucose, Mg+, Ca2+ (Gibco) without
serum for 24 hours.
Cytokines/growth factors/chemicals
Human IL-1β was purchased from PeproTech (Rocky Hills, New Jersey, USA), and Human
and mouse VEGF-165 (VEGFA) were purchased from CliniSciences (Nanterre, France).
Based on previous studies, Human IL-1β and Human VEGF-165 were routinely used at 10 ng/
mL [19,49]. Mouse VEGF-165 was used at a concentration of 20 ng/μL. The inhibitor of
FOXO1 total (AS1842856) was purchased from Merck (Kenilworth, New Jersey, USA) and
was used at 100 nM [50]. D-Mannitol was purchased from Sigma Aldrich (St. Louis, Missouri,
USA) and was used at 100 mM [51].
Antibodies
Anti-CLDN4 (mouse), anti-CLDN5 (mouse (tissues) and rabbit (cell culture)), anti-human
ZO1 (rabbit), and anti-GFAP (rat) were from Invitrogen (Carlsbad, California, USA). Anti-
CDH5 (goat) was from R&D systems (Minneapolis, Minnesota, USA). Anti-human CDH5
(mouse) and anti-human DHH (H-85) (rabbit) were from Santa Cruz Biotech (Santa Cruz,
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California, USA). Anti-FGB (rabbit) and anti-human PECAM1 (mouse) were from Dako (Car-
pinteria, California, USA). Anti-ALB (sheep) and anti-MBP (rat) were from Abcam (Cam-
bridge, Massachusetts, USA). Anti-CD45 (rat) was from eBioscience (San Diego, California,
USA). Anti-RNA binding fox-1 homolog 3 also known as neuronal nuclei antigen (NEUN)
(rabbit) and anti-AQP4 (rabbit) were from Millipore (Billerica, Massachusetts, USA). Anti-
LAM (rabbit) was from Sigma Aldrich (St. Louis, Missouri, USA). Anti-ZO1 (rabbit) was from
Life Technologies (Grand Island, New York, USA). Anti-FOXO1 (rabbit), anti-p-FOXO1 (rab-
bit), and anti-β-ACTIN (rabbit) were from cell signaling (Danvers, Massachusetts, USA).
Quantitative RT-PCR
RNA was isolated using Tri Reagent (Molecular Research Center) as instructed by the manu-
facturer, from 3 × 105 cells or from isolated mouse-enriched neurovascular fractions. For
qRT-PCR analyses, total RNA was reverse transcribed with Moloney Murine Leukemia Virus
(M-MLV) reverse transcriptase (Promega, Madison, Wisconsin, USA), and amplification was
performed on a DNA Engine Opticon2 (MJ Research, St. Bruno, Canada) using B-R SYBER
Green SuperMix (Quanta Biosciences, Beverly, Massachusetts, USA). Primer sequences are
reported in Table 1.
The relative expression of each mRNA was calculated by the comparative threshold cycle
method and normalized to β-actin mRNA expression.
Western blots
Protein expression was evaluated by SDS-PAGE. Protein loading quantity was controlled
using the rabbit monoclonal anti-β-actin antibody (cell signaling). Secondary antibodies were
from Invitrogen. The signal was then revealed by using an Odyssey Infrared imager (LI-COR,
Lincoln, Nebraska, USA). For quantification, the mean pixel density of each band was mea-
sured using Image J software (NIH, Bethesda, Maryland, USA), and data were standardized to
β-actin, and fold change versus control calculated.
Stereotactic injection
Ten-week-old C57BL/6 mice (4 mice per condition) were anaesthetized using isoflurane (3%
induction and 1% maintenance) (Virbac Schweiz, Glattbrugg, Germany) and placed into a ste-
reotactic frame (Stoelting Co., Illinois, USA). To prevent eye dryness, an ophthalmic ointment
was applied at the ocular surface to maintain eye hydration during the time of surgery. The
skull was shaved, and the skin incised on 1 cm to expose the skullcap. Then, a hole was drilled
into the skull, using a pneumatic station S001+TD783 Bien Air, until reaching the dura mater.
A total of 3 μl of murine VEGFA (20 ng/μL), 3 μL of healthy mouse plasma, or 3 μL of vehicle
control (PBS) were then delivered at 0.01 μl/s into the frontal cortex at coordinates of 1 μm
posterior to bregma, 2 μm left of the midline, and 1.5 μm below the surface of the cortex [36].
Mice received a subcutaneous injection of buprenorphine (0.05 mg/kg) (Ceva santé ani-
male, Libourne, France) 30 minutes before surgery and again 8 hours post-surgery to assure a
constant analgesia during the procedure and postoperatively. Mice were humanely killed by
pentobarbital (Richter Pharma, Wels, Austria) overdose at 24 hours post injection (dpi). For
histological assessment, the brain of each animal was harvested.
Experimental autoimmune encephalomyelitis (EAE)
Ten-week-old female mice were immunized by subcutaneous injection of 300-μg myelin oligo-
dendrocyte glycoprotein-35-55 (MOG35–55) (Hooke Laboratories, Lawrence, Massachusetts,
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USA) in 200-μl Freund’s Adjuvant containing 300-μg/mL mycobacterium tuberculosis H37Ra
(Hooke Laboratories) in the dorsum. Mice were administered with 500-ng pertussis toxin
(PTX) intraperitoneously on day of sensitization and 1 day later (Hooke Laboratories). The
emulsion provides antigen, which initiates expansion and differentiation of MOG-specific auto-
immune T cells. PTX enhances EAE development by providing additional adjuvant. EAE will
develop in mice 7 to 14 days after immunization (Day 0): Animals that develop EAE will
become paralyzed. Disease was scored (0, no symptoms; 1, floppy tail; 2, hind limb weakness
(paraparesis); 3, hind limb paralysis (paraplegia); 4, fore and hind limb paralysis; 5, death)) [31]
from day 7 post immunization until day 32 post immunization. At Day 32, all the animals were
euthanized by pentobarbital (Richter Pharma) overdose. For histological assessment, cervical,
lumbar, and dorsal sections of each animal spinal cord, as well as the spleen, were harvested.
Immunohistochemistry
Prior to tissue collection and staining, mice were transcardially perfused with PBS (10 mL) fol-
lowed by 10% Formalin (10 mL) to remove intravascular plasma proteins. Brain and spinal
cord samples were either fixed in 10% formalin for 3 hours, incubated in 30% sucrose
Table 1. List of primers used for RT qPCR.
mDhh F 50 -CTTGGACATCACCACGTCTG- 30
R 50 -ATGTAGTTCCCTCAGCCCCT- 30
mIcam1 F 50 -TGGCCTGGGGGATGCACACT- 30
R 50-CCACCGGGCTGTAGGTGGGT-30
mVcam1 F 50 -CGTACACCATCCGCCAGGCA- 30
R 50 -TAGAGTGCAAGGAGTTCGGGCG- 30
mCldn5 F 50 -GCAAGGTGTATGAATCTGTGCT- 30
R 50 -GTCAAGGTAACAAAGAGTGCCA- 30
mZo1 F 50 -GCTAAGAGCACAGCAATGGA- 30
R 50 -GCATGTTCAACGTTATCCAT- 30
mβ-actin F 50 -GAAGCTGTGCTATGTTGCTCTA- 30
R 50—GGAGGAAGAGGATGCGGCA- 30
hGfap F 50 -TGGGTCAAAGGAAACCGGAA- 30
R 50 -GAAAGTCCCAAGCCATCAGC- 30
hDhh F 50 -AACAGCTTACTTCCGGCTCC- 30
R 50 -CGACTCTTGTGGGCTCTGTT- 30
hIcam1 F 50 -ACGCCGGAGGACAGGGCATT- 30
R 50 -GGGGCTATGTCTCCCCCACCA- 30
hVcam1 F 50 -GGCCCAGTTGAAGGATGCGGG- 30
R 50 -AGAGCACGAGAAGCTCAGGAGAA- 30
hAldh1L1 F 50 -CCAGGGTTCTTCTTTGAGCCA- 30
R 50 -CACCAGAAGCCAGGCCAAAT- 30
hVim F 50 -CAGTTTTTCAGGAGCGCAAGA- 30
R 50 -CAAGTTGGTTGGATACTTGCTGG- 30
hCldn4 F 50 -GACACTAATGAGCCTGGGAGG- 30
R 50 -GTGCACAGGTCCCATTTATTGTAG- 30
hβ-actin F 50 -GCTGTGCTACGTCGCCCTG- 30
R 50 -GGAGGAGCTGGAAGCAGCC- 30
F, forward; R, reverse; RT qPCR, quantitative reverse transcription polymer chain reaction.
β-actin was used as the household gene.
https://doi.org/10.1371/journal.pbio.3000946.t001
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overnight, OCT embedded and cut into 9-μm thick sections, or directly OCT embedded and
cut into 9 μm thick sections. Cultured cells were fixed with 10% formalin for 10 minutes.
Human frozen sections were used directly without any prior treatment. Concerning the fixed
sections, for CLDN4, prior to blocking, sections were soaked in Citrate (pH 7.5; 100˚C). For
CLDN5, prior to blocking, sections were soaked in EDTA (pH 6.0; 100˚C). For CD45, sections
were treated with 0.5 mg/mL protease XIV (Sigma Aldrich) at 37˚C for 5 minutes. Primary
antibodies were used at 1:100 except CLDN4 (1:50), FGB (1:1,000), and ALB (1:1,000). Sam-
ples were examined using a Zeiss Microsystems confocal microscope (Oberkochen, Germany),
and stacks were collected with z of 1 μm.
For immunofluorescence analyses, primary antibodies were resolved with Alexa Fluor–con-
jugated secondary polyclonal antibodies (Invitrogen), and nuclei were counterstained with
DAPI (1:5000) (Invitrogen). For all immunofluorescence analyses, negative controls using sec-
ondary antibodies only were done to check for antibody specificity.
Morphometric analysis
Morphometric analyses were carried out using NIH ImageJ software (NIH).
BBB permeability was evaluated by measuring tight junction integrity and plasmatic protein
extravasation. Brain and spinal cord sections were immunostained for the expression of
CLDN5/CDH5 and FGB/IgG/ALB, respectively. For each brain or spinal cord section,
CLDN5+, CDH5+, FGB+, IgG+, and ALB+ areas were quantified in 20 pictures taken at the
margins of the lesion area under 40× magnification. One section was quantified per spinal
cord (3 different zones are displayed on the same section: 1 cervical, 1 lumbar, and 1 dorsal to
get a global vision of the lesion) (per mouse).
Leukocyte densities were evaluated in sections stained for the expression of CD45 leukocyte
population. For each brain or spinal cord section, CD45+ leukocytes were counted in 20 pic-
tures randomly taken under 40× magnification. One section was quantified per spinal cord (3
different zones are displayed on the same section: 1 cervical, 1 lumbar, and 1 dorsal to get a
global vision of the inflammatory lesion) (per mouse).
Demyelination was evaluated in spinal cord sections stained for the expression of MBP. For
each spinal cord section, MBP+ area was quantified in 10 pictures taken in and around inflam-
matory lesion sites under 20× magnification. One section was quantified per spinal cord (3 dif-
ferent zones are displayed on the same section: 1 cervical, 1 lumbar, and 1 dorsal to get a global
vision of the lesion) (per mouse).
Plasmatic protein and leukocyte infiltrate distribution at the neurovascular unit were evalu-
ated in brain or spinal cord sections (1) triple stained for PECAM1 or CDH5 (markers of the
BBB), IgG (plasmatic proteins), and AQP4 or GFAP (markers of the Glia Limitans); or (2)
double stained for IgG (plasmatic proteins), FITC Dextran (exogenous tracer) or CD45 (leuko-
cyte infiltrate), and LAM (marker of basement membranes). For each section, the distribution
(between the lumen, the PVS, and the parenchyma) of IgG, 70 kDa FITC Dextran or leukocyte
infiltrate was quantified for 5 to 6 neurovascular units randomly taken under 60× magnifica-
tion, each 1 from a different animal. We used negative working images highlighting the endo-
thelial BBB and astrocyte Glia Limitans and outlined them by using dotted lines. Dotted lines
were then transferred to the plasmatic protein or leukocyte infiltration images so that we could
quantify their distribution within the 3 compartments (lumen, PVS, and parenchyma).
Statistical analyses
Results are reported as mean ± SEM. Comparisons between groups were analyzed for signifi-
cance with the nonparametric Mann–Whitney U test, the nonparametric Kruskal–Wallis test
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followed by the Dunn multiple comparison test when we have more than 2 groups, the chi-
squared test for the distribution of plasmatic proteins and inflammatory cells in the neurovas-
cular unit, or a nonlinear regression test (Boltzmann sigmoidal) for the EAE scoring analysis
using GraphPad Prism v8.0.2 (GraphPad, San Diego, California, USA). Differences between
groups were considered significant when P� 0.05 (�P� 0.05, ��P� 0.01, ���P� 0.001).
Supporting information
S1 Text. Supporting information file containing the S1 Data and S2 Data legends and DOI
links (A), the Supporting Methods (B), and the associated References (C).
(DOCX)
S1 Raw Images. Supporting information file containing the original, uncropped, and mini-
mally adjusted images supporting all blot and gel results reported in Fig 2 panel G, Fig 4 panel
F, and Fig 7 panel I as well as S6 Fig panel A and B.
(PDF)
S1 Fig. (Related to Fig 1 and Fig 2). BMEC purity analysis shows limited contamination by
other neurovascular components (A) Primary BMECs from DhhECKO and control mice were
isolated and cultured on Lab-Tek. ZO1 (in green) and SMA, NG2, IBA1, or GFAP (in red)
localizations were evaluated by immunofluorescent staining of a confluent cell monolayer.
Nuclei were stained with DAPI (in blue). The experiment was repeated 3×. Mouse brain in
situ hybridization analysis highlights Dhh expression at the BBB. (B) C57BL/6 cortical
cross section hybridized with the Dhh RNA probe show Dhh expression in blood vessels. A
control section hybridized with the Dhh antisense RNA probe show the absence of hybridiza-
tion signals. MECs isolated from the spinal cord of mice induced with EAE MOG35-55 are
highly contaminated by leukocytes (C) Spinal cord MECs were isolated from 12-week-old
C57Bl/6 mice at day 13 post induction with EAE MOG35-55 or placebo and Pecam1, Cd45,
Sma, Ng2, and Gfap expressions were quantified by qRT-PCR (cycle threshold mean values)
before and after the cell suspension were depleted in CD45+ leukocytes. β-actin is used as a ref-
erence. A MACS CD45+ cell depletion step is sufficient to eliminate leukocyte contamina-
tion in MECs isolated from the spinal cord of mice induced with EAE MOG35-55 (D)
Representative graphs of flow cytometry analysis performed on C57BL/6 mouse spinal cord
MECs harvested at day 13 post EAE MOG35-55 induction. Analysis showed no CD45+ cell
population in samples depleted in leukocytes using the MACS CD45+ cell isolation kit (Milte-
nyi Biotec) (EAE MOG35-55 spinal cord MECs n = 3; EAE MOG35-55 spinal cord MECs
+ MACS CD45+ cell isolation n = 3). Dhh endothelial knockdown does not impact CNS
MEC viability in culture (E-F). (E) Primary CNS MECs from DhhECKO and control mice
were isolated and cultured on Lab-Tek and immunostained with Propidium Iodide (in red)
and Hoechst 33342 to label the nuclei (in blue). (F) DhhECKO versus control primary CNS
MEC viability was evaluated by quantifying the number of nuclei that incorporated Propidium
Iodide. NS, Mann–Whitney U test. The underlying data for S1 Fig can be found in S2 Data
(https://doi.org/10.6084/m9.figshare.12625085.v7).
(TIF)
S2 Fig. (Related to Fig 3, Fig 4, Fig 6 and Fig 7). Cadherin5CreERT2 recombinase activation
in blood vessels is successful and specific (A) Brain and spinal cord sections were harvested
from Cadherin5CreERT2,Rosa26mTmG mice and littermate controls and immunostained with
anti-GFP (in green) and anti-PECAM1 (in red) antibodies. Dhh endothelial knockdown does
not impact CNS angiogenesis (B) Spinal cord sections were harvested from DhhECKO mice
and littermate controls and immunostained with an anti-IB4 (in green) antibody. IB4 positive
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area was quantified (DhhECKO n = 7, control n = 6). (C) Cortical sections were harvested from
DhhECKO mice and littermate controls and immunostained with an anti-IB4 (in green) anti-
body. IB4 positive area was quantified (DhhECKO n = 6, WT n = 6). Dhh endothelial knock-
down does not impact brain angioarchitecture (D) The vascular network in the brain of
DhhECKO mice and control littermates was imaged by microcomputed tomography (micro-
CT). NS, Mann–Whitney U test. The underlying data for S2 Fig can be found in S1 Data (indi-
vidual numerical data (excel file)) and S2 Data (statistical analysis (Prism file)) (https://doi.
org/10.6084/m9.figshare.12625034.v6; https://doi.org/10.6084/m9.figshare.12625085.v7).
(TIF)
S3 Fig. Endothelial-specific Dhh inactivation induces BBB permeability in vivo. (A) Spinal
cord sections were harvested from DhhECKO mice and littermate controls and immunostained
with anti-IB4 (in green) and anti-CLDN5 (in red) antibodies. Representative IB4/CLDN5
staining was shown. (B–C) Spinal cord sections were harvested from DhhECKO mice and litter-
mate controls and immunostained with anti-CDH5 or anti-CLDN5 (in green), and anti-FGB
or anti-ALB (in red) antibodies. Representative (B) CDH5/FGB and (C) CLDN5/ALB staining
were shown.
(TIF)
S4 Fig. (Related to Fig 4). DhhECKO-induced BBB breakdown is sufficient to induce a sec-
ondary CNS protective barrier at the Glia Limitans. (A) Brain sections were harvested from
DhhECKO mice and littermate controls injected with 70 kDa FITC Dextran and (A) immunos-
tained with an anti-LAM (in red) antibody (nuclei were stained with DAPI (in blue)). Repre-
sentative LAM/FITC Dextran staining was shown. (B) Negative working images of LAM
channels were used to highlight the endothelial (EBM) and astrocyte (ABM) basement mem-
branes, using orange dotted lines. The outlines were then transferred to the FITC Dextran
images to discriminate the distribution of FITC Dextran between the lumen, PVS, and paren-
chyma. (C–D) The distribution of FITC Dextran within the lumen, PVS, and parenchyma was
quantified. (DhhECKO n = 6, control n = 6) P< 0.0001, 95% CI: 0.3518 to 0.5734, chi-squared
test. (E) Negative working images of AQP4/PECAM1 channels were used to highlight the
endothelial (EBM) and astrocyte (ABM) basement membranes, using orange dotted lines. The
outlines were then transferred to the IgG images to discriminate the distribution of IgG
between the lumen, PVS, and parenchyma. The underlying data for S4 Fig can be found in S2
Data (https://doi.org/10.6084/m9.figshare.12625085.v7).
(TIF)
S5 Fig. (Related to Fig 4). DhhECKO-induced BBB breakdown is sufficient to induce a sec-
ondary CNS protective barrier at the Glia Limitans. (A) Spinal cord sections were harvested
from DhhECKO mice and littermate controls and immunostained with anti-LAM (in green)
and anti-IgG (in red) antibodies (nuclei were stained with DAPI (in blue)). Representative
LAM/IgG staining was shown. (B) Negative working images of LAM channels were used to
highlight the endothelial (EBM) and astrocyte (ABM) basement membranes, using orange dot-
ted lines. The outlines were then transferred to the IgG images to discriminate the distribution
of IgG between the lumen, PVS, and parenchyma.
(TIF)
S6 Fig. (Related to Fig 4). Small intestine samples are used as a positive control for the
quantification of CLDN4 expression by western blot. (A) Representative blots of CLDN4
expression level on control mouse neurovascular unit lysates and mouse small intestine lysates
were shown. There is astrocyte reactivity but no astrocytic CLDN4 up-regulation at the
capillary level in DhhECKO mouse CNS. (B) Representative blots of GFAP and CLDN4
PLOS BIOLOGY Blood brain barrier disruption leads to astrocyte barrier formation
PLOS Biology | https://doi.org/10.1371/journal.pbio.3000946 November 30, 2020 26 / 30
expression level on DhhECKO and control lysates were shown. Lysates were obtained with neu-
rovascular units, which are 20 μm and larger. (C) GFAP expression level was quantified by
western blot on DhhECKO and control lysates obtained with neurovascular units, which are
20 μm and larger. (D) CLDN4 expression level was quantified by western blot on DhhECKO
and control lysates obtained with neurovascular units, which are 20 μm and larger. (DhhECKO
n = 6, WT n = 6). �P� 0.05, Mann–Whitney U test. The underlying data for S6 Fig can be
found in S2 Data (https://doi.org/10.6084/m9.figshare.12625085.v7).
(TIF)
S7 Fig. (Related to Fig 5 and Fig 7). Both VEGFA and Mannitol induce HBMEC permeabil-
ity in vitro. (A) Cultured HBMECs were treated with PBS, VEGFA, or Mannitol for 6 h, and
HBMEC monolayer permeability to 70 kDa FITC Dextran was quantified. Mice with endothe-
lial Dhh knockdown display a reinforced barrier at the Glia Limitans restraining access to
the parenchyma to inflammation in a model of multiple sclerosis: (B) Negative working
images of GFAP/CDH5 channels were used to highlight the endothelial (EBM) and astrocyte
(ABM) basement membranes, using orange dotted lines. The outlines were then transferred to
the FGB images to discriminate the distribution of FGB between the lumen, PVS, and paren-
chyma. (C) Negative working images of the LAM channel were used to highlight the endothe-
lial (EBM) and astrocyte (ABM) basement membranes, using blue dotted lines. The outlines
were then transferred to the CD45 images to discriminate the distribution of leukocytes
between the lumen, PVS, and parenchyma. �P� 0.05, ����P� 0.0001 Kruskal–Wallis test. The
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